Literature DB >> 20538984

Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration.

Long V Ly1, Inge H G Bronkhorst, Els van Beelen, Johannes Vrolijk, Andrew W Taylor, Mieke Versluis, Gregorius P M Luyten, Martine J Jager.   

Abstract

PURPOSE: The presence of an inflammatory phenotype, characterized by an increased expression of HLA antigens and an immunologic infiltrate, carries a bad prognosis in uveal melanoma. This study was conducted to determine whether the aqueous humor (AqH) from eyes with uveal melanoma contains inflammatory cytokines and whether their presence is associated with inflammation.
METHODS: Immediately after enucleation, AqH was obtained from 37 eyes containing uveal melanoma. Samples were stored at -80°C until use. Fifteen different cytokines were measured with a multiplex bead array. Intratumoral macrophages were analyzed by immunohistochemistry and immunofluorescence staining. The presence of specific cytokines was compared with histopathologic, genetic, and clinical tumor characteristics, as well as patient survival.
RESULTS: Several cytokines showed significantly higher expression in the AqH of uveal melanoma-containing eyes than in the AqH of eyes undergoing cataract surgery. MCP-3 was associated with the presence of CD68(+) macrophages. Correlations were found between some cytokine levels and a few known prognostic factors of uveal melanoma, but cytokine levels were not of predictive value for survival.
CONCLUSIONS: Uveal melanoma-containing eyes often carry increased levels of inflammation-related cytokines in their AqH. However, the presence of most specific cytokines was not related to the presence of macrophages, clinical or histopathologic parameters, or prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538984      PMCID: PMC3261048          DOI: 10.1167/iovs.10-5526

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  39 in total

1.  Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window.

Authors:  S R Boyd; D Tan; C Bunce; A Gittos; M H Neale; J L Hungerford; S Charnock-Jones; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.

Authors:  T Mäkitie; P Summanen; A Tarkkanen; T Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-06       Impact factor: 4.799

3.  Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death.

Authors:  Michael D Onken; Lori A Worley; Justis P Ehlers; J William Harbour
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

4.  [HLA class I antigen expression correlates with histological cell type in uveal melanoma].

Authors:  S Dithmar; J Crowder; M J Jager; N Vigniswaran; H E Grossniklaus
Journal:  Ophthalmologe       Date:  2002-08       Impact factor: 1.059

5.  Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities.

Authors:  Frank Tschentscher; Johannes Hüsing; Tanja Hölter; Elisabeth Kruse; Irina Gana Dresen; Karl-Heinz Jöckel; Gerasimos Anastassiou; Harald Schilling; Norbert Bornfeld; Bernhard Horsthemke; Dietmar Rudolf Lohmann; Michael Zeschnigk
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

6.  Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis.

Authors:  Jean-Philippe Herbeuval; Claude Lambert; Odile Sabido; Michèle Cottier; Pierre Fournel; Michel Dy; Christian Genin
Journal:  J Natl Cancer Inst       Date:  2003-04-16       Impact factor: 13.506

Review 7.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy.

Authors:  Antonio Sica; Tiziana Schioppa; Alberto Mantovani; Paola Allavena
Journal:  Eur J Cancer       Date:  2006-03-07       Impact factor: 9.162

8.  Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases.

Authors:  Päivi Toivonen; Teemu Mäkitie; Emma Kujala; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-01       Impact factor: 4.799

9.  Proteomics in uveal melanoma.

Authors:  Guy S Missotten; Jos H Beijnen; Jan E Keunen; Johannes M Bonfrer
Journal:  Melanoma Res       Date:  2003-12       Impact factor: 3.599

10.  Cytokine secretion by decidual lymphocytes in transient hypertension of pregnancy and pre-eclampsia.

Authors:  Jacek R Wilczyński; Henryk Tchórzewski; Ewa Głowacka; Małgorzata Banasik; Przemyslaw Lewkowicz; Marian Szpakowski; Krzysztof Zeman; Jan Wilczyński
Journal:  Mediators Inflamm       Date:  2002-04       Impact factor: 4.711

View more
  23 in total

1.  Immune oppression array elucidating immune escape and survival mechanisms in uveal melanoma.

Authors:  Fang Hou; Qi-Ming Huang; Dan-Ning Hu; Jost B Jonas; Wen-Bin Wei
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

Review 2.  Immunotherapy for uveal melanoma.

Authors:  Dae Won Kim; Jaime Anderson; Sapna P Patel
Journal:  Melanoma Manag       Date:  2016-05-19

Review 3.  Inflammation in uveal melanoma.

Authors:  I H G Bronkhorst; M J Jager
Journal:  Eye (Lond)       Date:  2012-12-14       Impact factor: 3.775

4.  Ciliary body melanoma - a particularly rare type of ocular tumor. Case report and general considerations.

Authors:  Mariana Costache; Oana Maria Patrascu; Dumitru Adrian; Diana Costache; Maria Sajin; Emil Ungureanu; Olga Simionescu
Journal:  Maedica (Buchar)       Date:  2013-09

5.  Impact of Adjuvant Ocular Interventions on the Quality of Life of Patients with Uveal Melanoma after Proton Beam Therapy.

Authors:  Johannes Gollrad; Christopher Rabsahl; Antonia M Joussen; Andrea Stroux; Volker Budach; Dirk Böhmer; Alexander Böker
Journal:  Ocul Oncol Pathol       Date:  2021-11-08

6.  Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Marie Najean; Stéphanie Lemaitre; Sylvain Dureau; Rémi Dendale; Christine Levy; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-07       Impact factor: 3.117

7.  IL-18 regulates melanoma VLA-4 integrin activation through a Hierarchized sequence of inflammatory factors.

Authors:  María Valcárcel; Teresa Carrascal; Olatz Crende; Fernando Vidal-Vanaclocha
Journal:  J Invest Dermatol       Date:  2013-08-12       Impact factor: 8.551

Review 8.  Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.

Authors:  Helena Kupcova Skalnikova; Jana Cizkova; Jakub Cervenka; Petr Vodicka
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

9.  Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines.

Authors:  Patrick Logan; Julia Burnier; Miguel N Burnier
Journal:  Ecancermedicalscience       Date:  2013-07-31

10.  Identification of intraocular inflammatory mediators in patients with endophthalmitis.

Authors:  Xiaoli Hao; Changxian Yi; Yuqin Wang; Jin Li; Fang Huang; Liwen He; Wei Chi
Journal:  Mol Vis       Date:  2016-06-02       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.